Divergent expression patterns of  mRNA and SATB1 protein in colorectal cancer and normal tissues by unknown
RESEARCH ARTICLE
Divergent expression patterns of SATB1 mRNA and SATB1
protein in colorectal cancer and normal tissues
Anna E. Kowalczyk & Janusz Godlewski & Bartlomiej E. Krazinski &
Jolanta Kiewisz & Agnieszka Sliwinska-Jewsiewicka &
Przemyslaw Kwiatkowski & Bartosz Pula & Piotr Dziegiel &
Jacek Janiszewski & Piotr M. Wierzbicki & Zbigniew Kmiec
Received: 12 November 2014 /Accepted: 8 January 2015 /Published online: 21 January 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Special AT-rich sequence-binding protein 1
(SATB1) is a ‘genome organizer,’ and it has been proposed
as a factor that affects the development and progression of
various human neoplasms, including colorectal cancer
(CRC). This study aimed to compare SATB1 expression in a
group of CRC patients and healthy subjects at the mRNA and
protein levels. We collected paired tumor tissue and un-
changed mucosa of the large intestine from 102 CRC patients
as well as 53 biopsies of normal colon mucosa obtained from
healthy patients during screening colonoscopy. Tissue sam-
ples were quantified for SATB1 mRNA by quantitative PCR,
while SATB1 protein expression was determined by Western
blotting and immunohistochemistry. SATB1 mRNA level in
tumor tissues was over twofolds lower than in samples of
corresponding unchanged tissues and fourfolds lower
than in biopsies of healthy colon mucosa. Western blot-
ting analysis revealed that SATB1 protein content in tu-
mor and unchanged tissues of CRC patients was over
sixfold and fivefolds higher than in biopsies of healthy
colon mucosa, respectively. Immunohistochemical stain-
ing demonstrated higher nuclear and cytoplasmic SATB1
reactivity in the tumor tissue compared to unchanged mu-
cosa of CRC patients. Despite these differences, SATB1
mRNA, protein, and immunoreactivity levels did not cor-
relate with patients’ clinicopathological data and their
overall survival, but the latter analysis was limited by a
relatively short period of follow-up. In conclusion, we
suggest that some as yet unidentified posttranscriptional
mechanisms that regulate SATB1 expression may be al-
tered in the CRC tissue.
Keywords SATB1 expression . Colorectal cancer . Normal
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Introduction
Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer accounting for about 10 % of total adult
malignancies worldwide. In 2008, there were approxi-
mately 1.2 million cases of newly diagnosed CRC and
over 600,000 people died of this malignancy [1]. A large
part of the malignancies are diagnosed at the late stage,
and thus, the major cause of death in individuals suffering
from CRC is distant metastasis. Death from CRC can be
prevented by the detection of early-stage disease. Over the
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past decades, a molecular background of CRC pathogen-
esis has been extensively screened for potential molecular
markers and therapeutic targets. Studies suggest a number
of factors which can influence the development of the
CRC including genetic factors. Gene activation or silenc-
ing can be regulated by changes in chromatin organiza-
tion. Special AT-rich sequence-binding protein 1 (SATB1)
is a nuclear matrix-associated protein which organizes the
structure of genome at the chromatin level. SATB1 forms
a docking site for the chromatin-modifying enzymes and
transcription activators or repressors and, as a potent epi-
genetic regulator, may affect the transcription of numer-
ous genes [2]. SATB1 can influence the expression of
more than 1000 genes, including those implicated in the
pathogenesis of human neoplasms [3]. This protein may
play a role in breast cancer cell proliferation [4] and was
found to be upregulated in several malignancies such as
breast, laryngeal, gastric, liver, and ovarian cancers [3,
5–8]. Results of many studies suggest that SATB1 over-
expression is associated with an aggressive phenotype of
tumor cells. In breast cancer, SATB1 was found to direct-
ly upregulate metastasis-associated genes while it de-
creased expression of tumor-suppressor genes and pro-
moted tumor growth and metastasis [3]. Silencing of
SATB1 expression in breast cancer cell lines restored nor-
mal acinar polarity and limited the ability of cells to grow
and metastasize in vivo. Moreover, ectopic SATB1 ex-
pression in a nonaggressive breast cancer cell line induced
the aggressive phenotype and metastatic activity in the
cells [3]. SATB1 overexpression can affect proteins medi-
ating cell-to-cell adhesion and promote epithelial-
mesenchymal transition (EMT) [3]. Altered SATB1 ex-
pression could be related to the occurrence and develop-
ment of multidrug resistance phenotype in breast cancer
[9]. In some studies, the expression level of SATB1 cor-
related with cancer progression and was suggested to be
an useful prognostic marker in breast cancer, laryngeal
squamous cell carcinoma, cutaneous melanoma, glioma,
gastric, and hepatocellular cancer [3, 5–7, 10]. Several
discrepancies considering the role of SATB1 in human
malignancies have been also documented. Iorns et al.
[11] concluded that SATB1 had no role in breast cancer
pathogenesis, contradicting the results of the abovementioned
study [3]. In one study of non-small cell lung cancer, the
loss of SATB1 expression was associated with poor sur-
vival [12], while in another study of the same cancer
type, the opposite relationship was proposed, demonstrat-
ing the highest level of SATB1 mRNA in metastatic can-
cers [13]. Altogether, the reports suggest that SATB1 can
be expressed in a tissue-typical manner, and prognostic
value of SATB1 may be cancer-type specific; however,
contradictory results could be observed even in the same
tumor type.
SATB1 expression levels have been examined in tumor and
unchanged tissue samples of patients suffering from rectal or
colorectal cancer [14–18], but so far, there was no comparison
of the level of SATB1 expression in CRC tissue and normal
colon mucosa of healthy subjects. Moreover, in some aspects,
as the difference in the level of SATB1 expression in CRC
tissue and its prognostic significance, the results of mentioned
studies were inconsistent. Therefore, the main objective of our
study was to analyze and compare SATB1 gene expression in
samples of tumor and unchanged colorectal tissues of CRC
patients as well as in mucosal colon biopsies in a group of
healthy subjects. Quantitative real-time PCR and Western
blotting techniques were used to assess SATB1 mRNA and
SATB1 protein levels, respectively. An immunohistochemical
detection of SATB1 protein was carried out to localize its
expression pattern within the tested tissues of CRC patients.
Materials and methods
Patients
The specimens were obtained from two Polish surgical clinics
(Hospital of the Ministry of Internal Affairs and Administra-
tion in Olsztyn and Hospital of the Medical University of
Gdansk) and the gastrointestinal endoscopic unit (Hospital
of the Ministry of Internal Affairs and Administration in Olsz-
tyn) from 2010 to 2012. The study included 102 patients with
CRC (demographic and clinicopathological data are presented
in Table 1). None of the CRC patients had a second neoplastic
disease or had previously undergone chemo- or radiotherapy.
The control group consisted of 53 healthy individuals (14
males and 39 females, average age 57.3±6.83 years, range
36–82 years; mean±SD) who underwent colonoscopy as part
of routine surveillance for CRC (within the National screening
program for early detection of colorectal cancer). Control sub-
jects had no family history of CRC. None of the CRC patients
or healthy individuals suffered from inflammatory bowel dis-
ease. Clinical and demographic data were obtained at the time
of enrollment. Median follow-up time was 36.2 months. Writ-
ten informed consent was obtained from each patient included
in the study. All procedures were performed in accordance
with the ethical standards and were approved by the Bioethics
Committee of the University of Warmia and Mazury in
Olsztyn.
Collection of colorectal samples
All steps of material collection were standardized in all
collaborative clinics. CRC samples were obtained during
surgical hemicolectomy, and control group specimens
were collected during colonoscopy. In CRC patients’
group, two types of matched samples were taken within
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20 min after tumor resection: (i) tumor tissue and (ii)
macroscopically unchanged mucosa from a distant part
of resected large intestine. Specimens were immediately
cut in two samples (5×5×5 mm) for quantitative PCR
(qPCR) and Western blotting (WB) analyses, frozen in
liquid nitrogen, and stored at −80 °C, whereas for routine
histological evaluation and immunohistochemistry (IHC),
the samples were fixed in 10 % neutral buffered formalin
and further processed into paraffin blocks. In the control
group of healthy patients, one biopsy (2×2×2 mm) was
fixed in 10 % neutral buffered formalin for routine histo-
logical examination, and two specimens from the adjacent
location to the biopsy site were collected for qPCR or WB
assays. Colonoscopic biopsies for qPCR analysis were
immediately placed in sterile vials containing RNAlater
(Sigma-Aldrich, St. Louis, MO, USA) and stored at
−20 °C until further analysis, while for WB assay, the
procedure was the same as for CRC samples.
Total RNA extraction and reverse transcription
Total RNAwas extracted from paired samples of cancer tissue
and unchanged mucosa derived from 69 CRC patients and 36
colonoscopic biopsies of healthy subjects using a Total RNA
Prep Plus kit (A&A Biotechnology, Gdynia, Poland), accord-
ing to the procedure provided. Isolated RNA was quantified
with spectrophotometry (NanoDrop 1000, NanoDrop prod-
ucts, Wilmington, DE, USA). Reverse transcription was car-
ried out in a vial containing 20 μl reaction mixture of 2 μg of
total RNA, 0.5μg of oligo dT primers (Sigma-Aldrich), 200U
of RevertAid™ Reverse Transcriptase, 20 U of RiboLock™
RNase Inhibitor, and 1 mM of each dNTP (all Thermo Scien-
tific, Waltham, MA, USA). Reactions were conducted accord-
ing to the manufacturer’s instructions. Resulting cDNAs were
diluted sixfold with sterile water and stored at −20 °C until
further use.
Real-time quantitative PCR
Quantification of SATB1 gene expression was carried out
using ABI 7500/7500 Fast Real-Time PCR System (Life
Technologies-Applied Biosystems, Foster City, CA,
U SA ) . β - A c t i n (ACT B ) a n d h y p o x a n t h i n e
phosphoribosyltransferase 1 (HPRT1) genes were used
as an internal control to normalize the transcript levels
of SATB1. qPCR conditions were validated and showed
90–100 % efficiency for all assays. The amplification
primer pairs were 5′-AGCAGGAAATGAAGCGTGCT
AAAG-3′ and 5′-GATCATGGAGAGGTTCTCCCAC
AG-3′ for SATB1, 5′-TGTGCCCATCTACGAGGGGTAT
GC-3′ and 5′-GGTACATGGTGGTGCCGCCAGACA-3′
for ACTB, 5′-GACTTTGCTTTCCTTGGTCAGGC-3′
and 5 ′-TGGCGATGTCAATAGGACTCCAG-3 ′ for
HPRT1. The reaction mixture (20 μl) included 2.4 μl of
cDNA, 0.2 μmol/l each of forward and reverse primers,
and 10 μl of Fast SYBR® Green PCR Master Mix (Life
Technologies—Applied Biosystems). The following gen-
eral qPCR conditions were applied: initial denaturation
for 20 s at 95 °C, followed by 40 cycles of denaturation
at 95 °C for 3 s, and annealing and elongation at 58 °C for
30 s (SATB1), 60 °C for 40 s (ACTB), or 62 °C for 40 s
(HPRT1). All samples were amplified in duplicates. Stan-
dard curves consisting of serial dilutions of the appropri-
ate cDNA were used to control the efficiency of qPCR
reactions. After qPCR, melting curves were obtained by
stepwise increases in temperature from 60 to 95 °C to
ensure that a single product was amplified in the reaction.
No template control reactions were performed for each
qPCR run. Selected PCR products were subjected to gel
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electrophoresis which confirmed their predicted size. Rel-
ative quantification of SATB1 expression was evaluated
using the ΔΔCt method [19]. The fold change in the
relative SATB1 gene expression was determined by calcu-
lating the 2−ΔΔCt value. Fold increase above 1 (2−ΔΔCt
>1) indicated SATB1 overexpression in CRC and fold de-
c r ea s e unde r 1 (2−ΔΔC t <1 ) i nd i ca t ed SATB1
downregulation.
Protein isolation and Western blotting analysis
Paired samples of tumor tissue and unchanged mucosa de-
rived from 32 CRC patients and 17 colonoscopic biopsies
were homogenized in RIPA lysis buffer supplied with 1:100
protease inhibitor cocktail, 1:100 phosphatase inhibitor cock-
tail 2, and 5 mM EDTA (all Sigma-Aldrich). Homogenates
were briefly centrifuged to remove tissue debris. Then, sam-
ples were centrifuged twice at 9000g for 10 min at 4 °C. The
protein content in the supernatant was determined by the
Bradford method [20]. Samples were aliquoted and stored at
−80 °C until further use.
To determine the level of SATB1 protein in tissue lysates,
the SDS-PAGE followed by Western blotting assays were
performed. Isolated protein fractions were denatured for
5 min at 95 °C and loaded on polyacrylamide gel (30 μg/lane).
Molecular weight standard (Spectra Multicolor Broad Range
Protein Ladder, Thermo Scientific) and protein extracts from
human tonsils (a positive control) were included into each
blotting experiment. Gels were run at the 10 mA/gel during
migration in the stacking gel and 15 mA/gel in the separating
gel (10 %). Proteins were transferred onto PVDF membrane
(Western blot membrane, Roche,Mannheim, Germany). Blots
were blocked in 5 % nonfat dry milk dissolved in Tris-
buffered saline pH 7.5 with 0.1 % Tween-20 (TBS-T) follow-
ed by overnight incubation at 4 °C with a primary rabbit poly-
clonal anti-human SATB1 antibody (diluted 1:1000 in TBS-T
buffer; #3650, Cell Signaling Technology, Danvers, MA,
USA). A rabbit polyclonal anti-human actin antibody (diluted
1:100 in TBS-T; #A2066, Sigma-Aldrich) was used to con-
firm equal loading of proteins. Primary antibodies were
washed out with TBS-T. The membranes were treated with
the specific HPR-conjugated goat anti-rabbit IgG secondary
antibodies (diluted 1:5000 in TBS-T; #A0545, Sigma-Al-
drich) for 90 min at room temperature (RT), developed with
an enhanced chemiluminescence (SuperSignal West Pico
Chemiluminescent Substrate, Thermo Scientific), and visual-
ized with G:BOX iChemi XR imaging system (Syngene,
Cambridge, UK). Band intensity was quantified using ImageJ
software (NIH, Bethesda, MD, USA). Positive SATB1 con-
trol—human tonsil extract—was used to normalize SATB1
quantities between individual blotting experiments. For the
negative control, SATB1 antibody was omitted and substitut-
ed with phosphate-buffered saline (PBS). Optical density
(OD) ratios between tumor and the corresponding unchanged
tissue of CRC patients were calculated. The ratios higher than
1 indicated that the expression of SATB1 protein was upreg-
ulated in CRC while those lower than 1 were regarded as
downregulated.
Immunohistochemical staining
SATB1 immunoreactivity was analyzed in 102 tumor and 39
unchanged large-intestine tissues sampled from CRC patients.
Immunohistochemistry was performed on 4-μm-thick paraf-
fin sections in Autostainer Link48 (DakoCytomation,
Glostrup, Denmark) to ensure repeatable reaction conditions.
The sections were first boiled in Target Retrieval Solution
buffer (pH 9) using a Pretreament Link Platform (both
DakoCytomation) in order to retrieve the antigens. The sec-
tions were then cooled in a rinsing buffer (TBS/0.05 %
Tween) and endogenous peroxidase activity was blocked by
incubation with EnVision FLEX Peroxidase-Blocking Re-
agent (DakoCytomation). After rinsing the sections with
TBS/0.1 % Tween, rabbit monoclonal primary antibody di-
rected against SATB1 (1:100, EPR3951, GeneTex, Irvine,
CA, USA) was applied for 20 min at RT. Sections were then
washed in TBS/0.05 % Tween and EnVision FLEX reagent
was applied in accordance with the manufacturer’s instruc-
tions to visualize the studied antigens. After washing the sec-
tions in TBS/0.05 % Tween, EnVision FLEX/HRP secondary
antibody was applied (20 min at RT). In the next step, the
substrate for peroxidase, diaminobenzidine, was applied, and
the sections were incubated for 10 min at RT. Last, the sec-
tions were counterstained with Mayer’s hematoxylin,
dehydrated in alcohols (70, 96, 99.8 %) and xylene, and final-
ly mounted using the SUB-X Mounting Medium
(DakoCytomation). As positive immunoreactive control for
the SATB1, a CRC specimen previously characterized by high
SATB1 expression in cancer cells and lymphocytes was used,
whereas the negative controls were performed by omitting the
primary antibody.
Evaluation of immunohistochemical reactions
The SATB1 immunostained sections were evaluated using
Olympus BX53 light microscope (Olympus, Tokyo, Japan)
by two independent pathologists who were blinded to the
patients’ clinical data. In doubtful cases, reevaluation was per-
formed unt i l a consensus was achieved. SATB1
immunoexpression was assessed in whole tissue sections in
cancer cells and non-transformed, normal cells of the mucosa
according to the immunoreactive score (IRS) of Remmele and
Stegner [21]. The scale is based on the percentage of cells
showing positive reaction (0 points: absence of cells with pos-
itive reaction, 1 point: 1–10 % cells, 2 points: 11–50 %, 3
points: 51–80 %, 4 points: over 80 % cells with positive
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reaction), as well as reaction intensity (0: no reaction, 1: low
intensity reaction, 2: moderate intensity reaction, 3: intense
reaction). The final score is the product of both parameters
and ranges from 0 to 12 points. The IRS method was used
for separate assessment of both nuclear as well as cytoplasmic
SATB1 expression in enterocytes and cancer cells. Based on
median expression values, CRC cases which showed a nuclear
SATB1 expression less than or equal to four IRS scores were
regarded as having ‘low’ expression, whereas those scored
more than four were regarded as ‘high’ SATB1 expression.
In the case of cytoplasmic SATB1 immunoreactivity, cases
showing no expression were regarded as ‘negative’ and those
scoring one or more were regarded as ‘positive’.
Statistical analyses
Statistical analyses were performed using Prism 5 (GraphPad,
La Jolla, CA, USA) and STATISTICA v.10 (StatSoft, Tulsa,
OK, USA) software. The differences in SATB1 mRNA and
SATB1 protein levels between matched tumor and unchanged
samples of CRC patients were examined by the Wilcoxon
matched-pairs test, whereas differences between colon muco-
sa biopsies of healthy subjects and tissues of CRC patients
were assessed by Mann-Whitney U tes t . SATB1
immunoexpression was analyzed utilizing the Mann-
Whitney U test and Wilcoxon matched-pairs test. The corre-
lations between the demographic, clinicopathological, and
molecular parameters were analyzed by the Fisher’s exact test.
Survival curves were plotted using Kaplan-Meier method.
The statistical significance of differences in survival between
groups of patients based on various variables (level of SATB1
expression and demographic and clinicopathological charac-
teristics) was evaluated using the log-rank test and Cox regres-
sion method. In all the analyses, results were considered sta-
tistically significant when P<0.05.
Results
SATB1 mRNA expression in CRC tissues is downregulated
To determine the expression of SATB1 at the mRNA level,
matched tumor and unchanged tissues derived from CRC pa-
tients and colonic biopsies of healthy group were subjected to
qPCR analysis. SATB1 mRNAwas found in all studied tissue
samples of CRC patients and colonic biopsies of healthy in-
dividuals. The expression of SATB1 mRNA in healthy colon
mucosa and unchanged tissue of CRC patients was signifi-
cantly elevated when compared to the tumor tissues (1.00±
0.01 and 0.53±0.01 vs. 0.25±0.01, respectively; P<0.0001;
Fig. 1). SATB1 mRNA level was higher in the colon mucosa
of healthy individuals than in unchanged tissues of CRC
patients (1.00±0.01 vs. 0.53±0.01; P<0.0001; Fig. 1).
Among the 69 tumor specimens tested, the relative SATB1
mRNA level (tumor tissue vs. matching unchanged mucosa
of CRC patients) was decreased in 51 (73.9 %) tumors while it
was increased in 18 (26.1 %) cases (Table 2).
The lack of correlation between SATB1 mRNA expression
and clinicopathological features
To assess the impact of SATB1 expression at the mRNA level
on CRC pathogenesis, the relationships between SATB1
mRNA content and selected demographic and clinicopatho-
logical parameters were tested. The relative SATB1 mRNA
level did not correlate with patients’ sex, age, tumor localiza-
tion, TNM disease stage, depth of invasion, lymph node in-
volvement, and the presence of metastases (Table 2).
For the reason that the groups of CRC patients and healthy
controls differed in terms of gender ratio and mean age, the
possible correlations between these parameters and the ex-
pression levels of SATB1mRNA had to be excluded. Pearson
correlation and Mann-Whitney U test proved the lack of sig-
nificant relationships (P>0.05; data not shown); and there-
fore, we assumed that this diversity had no impact on the
performed analyses.
SATB1 protein content is elevated in tissues of CRC patients
To determine the expression of SATB1 at the protein level,
matched tumor and unchanged tissues derived from CRC pa-
tients and colonic biopsies of healthy group were subjected to
Western blotting analysis. SATB1 protein was found in all
studied tissues of CRC patients and colon mucosa of healthy
subjects. SATB1 protein content in both tumor and unchanged
tissue samples of CRC patients was significantly higher than
the amount of SATB1 protein in colonic biopsies of the
Fig. 1 SATB1 mRNA levels in the tumor and unchanged large-intestine
tissues of CRC patients and normal colon mucosa of healthy subjects.
Expression of SATB1 mRNA (mean±SEM) is shown in relation to the
value obtained for healthy controls (1.0). ***P<0.001
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healthy group (6.23±0.86 and 5.42±0.89 vs. 1.00±0.13, re-
spectively; P<0.0001; Fig. 2). The average content of SATB1
protein in tumor tissue was similar to that in unchanged mu-
cosa of the large intestine of CRC patients (6.23±0.86 vs.
5.42±0.89, respectively; P=0.56; Fig. 2). Among 32 tumor
tissue specimens tested, the relative content of SATB1 protein
(tumor tissue vs. matching unchanged mucosa of CRC pa-
tients) was downregulated in 15 (46.9 %) tumors while it
was upregulated in 17 (53.1 %) cases (Table 3).
For the reason that the groups of CRC patients and healthy
controls differed in terms of gender ratio and mean age, the
possible correlations between these parameters and the levels
of SATB1 protein had to be excluded. Pearson correlation and
Mann-Whitney U test proved the lack of significant relation-
ships (P>0.05; data not shown), and therefore, we assumed
that this diversity had no impact on the performed analyses.
Nuclear and cytoplasmic SATB1 immunoreactivity is
elevated in CRC tissues
Immunohistochemical examination of SATB1 expression in-
cluded two sub-analyses: total 102 tumor cases vs. 39
unchanged colon tissues of CRC patients (Fig. 4a, b) and
matched tumor vs. normal colon samples from 39 CRC
patients.
Nuclear and cytoplasmic SATB1 expression was noted in
enterocytes as well as cancer cells of the analyzed tissues
(Fig. 3). In addition, SATB1 immunoreactivity was shown in
some stromal mononuclear cells, but theywere not included in
the analysis.
SATB1 nuclear expression was noted in cancer cells in 86/
102 (84.3 %) of the analyzed CRC cases, whereas in
enterocytes of unchanged large-intestine tissues, its expres-
sion was seen in 28/39 (71.8 %) cases. Statistical analysis
revealed that the SATB1 immunoreactivity was significantly
higher in cancer cells of all the analyzed CRC cases as com-
pared to its expression noted in cells of the unchanged mucosa
(IRS 4.36±0.38 vs. 1.74±0.31, respectively; P<0.0001;
Fig. 4a). Similar observations were noted when only 39
matched CRC and unchanged large intestine samples were
analyzed (IRS 4.62±0.62 vs. 1.74±0.31; P<0.0001). Cyto-
plasmic SATB1 expression was noted in cancer cells in 31/
102 (30.4 %) CRC cases; however, unchanged large-intestine
tissue enterocytes showed cytoplasmic immunoreactivity only
Table 2 Associations between clinicopathological features of studied CRC patients and the relative mRNA expression of SATB1 in colorectal tumor
tissues












Total 69 100.0 51 73.9 18 26.1
Sex
Male 35 50.7 29 82.9 6 17.1 0.1055
Female 34 49.3 22 64.7 12 35.3
Age (years)
≤67 31 44.9 21 67.7 10 32.3 0.4092
>67 38 55.1 30 78.9 8 21.1
Localization
Cecum, ascending, and transverse
colon
26 37.7 17 65.4 9 34.6 0.4081
Descending and sigmoid colon 16 23.2 12 75.0 4 25.0
Rectum 27 39.1 22 81.5 5 18.5
Depth of invasion (pT status)
T1+T2 8 11.6 7 87.5 1 12.5 0.6705
T3+T4 61 88.4 44 72.1 17 27.9
Lymph nodes (pN status)
N0 36 52.2 25 69.4 11 30.6 0.4219
N1+N2 33 47.8 26 78.8 7 21.2
Metastasis (pM status)
M0 57 82.6 43 75.4 14 24.6 0.4966
M1 12 17.4 8 66.7 4 33.3
TNM stage
I+II 32 46.4 23 71.9 9 28.1 0.7874
III+IV 37 53.6 28 75.7 9 24.3
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in 3/39 (7.7 %) cases. The intensity of cytoplasmic SATB1
expression was significantly higher in cancer cells as com-
pared to its expression in enterocytes, whether all CRC (IRS
1.14±0.21 vs. 0.2±0.13; P<0.01; Fig. 4b) or only paired
samples (IRS 1.13±0.33 vs. 0.2±0.13; P<0.05) were ana-
lyzed. No correlation between the presence of nuclear and
cytoplasmic SATB1 immunoreactivity was noted in cancer
cells or enterocytes.
The lack of correlation between SATB1 protein content
and clinicopathological features
Possible correlations of SATB1 expression at the protein level
with selected demographic and clinicopathological parame-
ters were analyzed based on the results obtained by Western
blotting and immunohistochemical analyses (Tables 3 and 4,
respectively). SATB1 protein levels, nuclear as well as cyto-
plasmic immunoreactivity did not correlate with patients’ sex,
age, tumor localization, TNMdisease stage, depth of invasion,
Table 3 Associations between clinicopathological features of studied CRC patients and the relative SATB1 protein levels (assessed by Western
blotting) in colorectal tumor tissues
Parameter Number of cases Percentage
(%)
SATB1 protein levels in tumor vs. unchanged tissues
of CRC patients
P values






Total 32 100.0 15 46.9 17 53.1
Sex
Male 15 46.9 5 33.3 10 66.7 0.1777
Female 17 53.1 10 58.8 7 41.2
Age (years)
≤67 14 43.8 5 35.7 9 64.3 0.3075
>67 18 56.3 10 55.6 8 44.4
Localization
Cecum, ascending, and transverse
colon
14 43.8 9 64.3 5 35.7 0.0954
Descending and sigmoid colon 7 21.9 1 14.3 6 85.7
Rectum 11 34.4 5 45.5 6 54.5
Depth of invasion (pT status)
T1+T2 7 21.9 3 42.9 4 57.1 1.0000
T3+T4 25 78.1 12 48.0 13 52.0
Lymph nodes (pN status)
N0 23 71.9 10 43.5 13 56.5 0.6989
N1+N2 9 28.1 5 55.6 4 44.4
Metastasis (pM status)
M0 29 90.6 13 44.8 16 55.2 0.5887
M1 3 9.4 2 66.7 1 33.3
TNM stage
I+II 22 68.8 10 45.5 12 54.5 1.0000
III+IV 10 31.3 5 50.0 5 50.0
Fig. 2 SATB1 protein levels in the tumor and unchanged large-intestine
tissues of CRC patients and normal colon mucosa of healthy subjects.
Representative blots of studied tissues are shown above the graph. β-
Actin (ACTB) was used as loading control. Bars represent mean±
SEM. *** P<0.001
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lymph node involvement, and the presence of metastases
(Tables 3 and 4).
The patients’ overall survival time is not associated
with the level of SATB1 expression in CRC tissues
To assess the significance of the SATB1 expression level as a
prognostic factor, 102 patients were followed up for
36.2 months. During this observation period, 38 (37.3 %) pa-
tients died.
The expression of SATB1 at the mRNA and protein levels,
as well as intensity of nuclear or cytoplasmic SATB1 immu-
noreactivity did not correlate with patients’ overall survival
(Table 5; Fig. 5a–d). Of the analyzed clinicopathological and
demographic parameters, advanced age at diagnosis
(>67 years; P=0.0016; Table 5; Fig. 5e), lymph node involve-
ment (P=0.0015; Table 5; Fig. 5f), the presence of metastases
(P<0.0001; Table 5; Fig. 5g), and TNM disease stage (III–IV;
P<0.0001; Table 5; Fig. 5h) were associated with poor patient
outcome.
Discussion
SATB1 can globally regulate expression of many genes by
tethering numerous gene loci and assembling them with chro-
matin remodeling enzymes and transcription factors. It has
been found that SATB1 is predominantly expressed in thymo-
cytes and regulates the spatiotemporal expression of numer-
ous genes involved in T cell proliferation, development, and
differentiation [22]. SATB1 has also been proposed as an im-
portant factor that controls the development and progression
of various human neoplasms [10]; however, its role in cancer
pathogenesis has yet not been fully elucidated.
The major finding of our study was the demonstration of
the lower SATB1 mRNA content in tumor tissue and un-
changed mucosa of CRC patients than in the normal colon
mucosa, while SATB1 protein contents in colorectal tissues
of CRC patients were significantly higher than those in the
colonmucosa of healthy controls. It appears that the high level
of SATB1 transcript expression in normal mucosa of healthy
subjects was accompanied by relatively low SATB1 protein
content. Thus, our observations suggest that in normal muco-
sa, posttranscriptional events limit the SATB1 expression, and
this regulation becomes disturbed in colorectal carcinoma.
This is a novel observation since SATB1 expression has not
previously been studied in normal colon mucosa of healthy
Fig. 4 SATB1 protein expression
in the tumor and unchanged
tissues of the large intestine of




and tumor cells. Bars represent
mean±SEM. *** P<0.001
Fig. 3 Immunohistochemical staining of SATB1 protein in
representative unchanged and tumor tissues of CRC patients. a Nuclear
and b dominant cytoplasmic immunoreactivity of SATB1 in unchanged
colon tissue; c intensive nuclear, d low nuclear, e dominant cytoplasmic,
and f combined nuclear and cytoplasmic immunoreactivity in tumor
tissue. Magnification ×200
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individuals, although it was determined in CRC tumor tissue
[14–18].
Various mechanisms may be involved in the posttranscrip-
tional modifications of SATB1 expression. SATB1 expression
can be regulated posttranscriptionally bymicro-RNAs (miRs).
In breast cancer cells, miR-488 downregulated SATB1 ex-
pression, and suppression of this miR resulted in SATB1-
mediated EMT [23]. Also, miR-7 and miR-155 were shown
to be involved in the posttranscriptional regulation of SATB1
gene expression in breast cancer cells [24]. SATB1 expression
in COLO205 colon cancer cells was downregulated by statins
via posttranslational modifications of SATB1 protein which
led to targeting it for proteolytic degradation [25]. Dysregula-
tion of hypothetical SATB1 expression-controlling mecha-
nism in colorectal tissue could lead to an aberrant SATB1
expression and result in global, tumor-promoting changes in
affected cells. Further investigations, including the analysis of
different epigenetic mechanisms potentially targeting SATB1
expression, are needed to delineate the differences observed
between mRNA level and protein content in the studied colo-
rectal tissues.
SATB1 expression and its role in colorectal cancer have
been investigated in five studies in which samples of tumor
and noncancerous colorectal tissues of CRC patients were
compared; however, the colon mucosa of healthy individuals
was not investigated [14–18]. It has to be noted that in none of
these investigations the CRC samples were examined by the
combination of three different techniques (qPCR, Western
blotting, and IHC) as reported in our study. Meng et al. [14]
studied only rectal cancer tissue and found a prominent het-
erogeneity in the expression of SATB1 mRNA since 45/93
patients showed increased and 48/93 decreased levels of
SATB1 transcripts while the average level of SATB1 mRNA
in tumor tissue was statistically higher than that in unchanged
mucosa. These results are in contrast with our observations in
which 81.5 % of rectal cancers had decreased levels of SATB1
mRNA. In most cases of colorectal tumors, we found lower
SATB1 mRNA levels in comparison with unchanged colon
mucosa. Completely opposite results were reported by Al-
Sohaily et al. [18] who found high SATB1 mRNA expression
in 86 % of CRC tissues and lower immunoreactivity of
SATB1 protein in CRC cells in comparison to adjacent non-
cancerous tissues. To assess the localization and levels of
SATB1 protein expression in tissues of CRC patients, we also
used immunohistochemical staining. We revealed nuclear and
cytoplasmic immunoreactivity of the SATB1 protein in cancer
cells as well as in cells of unchanged tissues; however, the
nuclear expression was dominant. Our finding of higher
Table 4 Associations between clinicopathological features of studied CRC patients and SATB1 nuclear immunoreactivity in tumor cells
Parameter Number of cases Percentage (%) SATB1 nuclear immunoreactivity in CRC tissues
IRS≤4 Percentage (%) IRS>4 Percentage (%) P values
Total 102 100.0 61 59.8 41 40.2
Sex
Male 54 52.9 34 63.0 20 37.0 0.5469
Female 48 47.1 27 56.2 21 43.8
Age (years)
≤67 49 48.0 29 59.2 20 40.8 1.0000
>67 53 52.0 32 60.4 21 39.6
Localization
Cecum, ascending, and transverse colon 37 36.3 21 56.8 16 43.2 0.8939
Descending and sigmoid colon 26 25.5 16 61.5 10 38.5
Rectum 39 38.2 24 61.5 15 38.5
Depth of invasion (pT status)
T1+T2 14 13.7 8 57.1 6 42.9 1.0000
T3+T4 88 86.3 53 60.2 35 39.8
Lymph nodes (pN status)
N0 55 53.9 34 61.8 21 38.2 0.6892
N1+N2 47 46.1 27 57.4 20 42.6
Metastasis (pM status)
M0 87 85.3 53 60.9 34 39.1 0.5827
M1 15 14.7 8 53.3 7 46.7
TNM stage
I+II 51 50.0 32 62.7 19 37.3 0.6865
III+IV 51 50.0 29 56.9 22 43.1
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SATB1 nuclear immunoreactivity in CRC tumor than in the
matched noncancerous mucosa is in line with the results of
other authors [14–17], although there are differences in the
percentage of immunopositive tissues. Using only IHC, Nodin
et al. [15] analyzed the expression of SATB1 protein by tissue
arrays in 529 cases of CRC and 16 samples of adjacent,
benign-appearing colorectal mucosa. They found that
58.0 % of the tumors were SATB1 immunonegative, and
among samples of control tissues, 87.5 % were denoted as
having negative expression. Fang et al. [17] observed positive
immunoreactivities in CRC in 53 % of tissue samples, com-
pared with only 10 % in the adjacent mucosa tissue cells,
while Zhang et al. [16], in 58.8 and 2.5 %, respectively. We
have noted nuclear SATB1 expression in 84.3 % of CRC
tissues and 71.8 % of noncancerous mucosa of the large in-
testine. These discrepancies may partly result from methodo-
logical differences, such as the type of antibody used or a way
of estimating of immunoreactivity; however, it is difficult to
find an explanation for the divergent results of Al-Sohaily
et al. [18].
In addition to nuclear SATB1 immunoreactivity, we also
observed that SATB1 protein was present in the cytoplasm of
cancer cells of 30.4 % studied CRC patients. Nakayama et al.
[26] demonstrated that the localization of SATB1 protein in
the cytoplasm could be attributed to the single point mutation
within the N-terminal nuclear targeting determinant of
SATB1. Further studies are needed to elucidate whether the
elevated cytoplasmic expression of SATB1 in CRC tumors in
Table 5 Analysis of overall survival of CRC patients in relation to their clinicopathological characteristics and SATB1 expression
Parameter Deaths / Cases Percentage (%) HR 95 % CI of ratio P values
SATB1 mRNA
Downregulated 21 / 51 41.2 (1.00) 0.4748 to 2.796 0.7542
Upregulated 7 / 18 38.9 1.15
SATB1 protein
Downregulated 3 / 15 20.0 (1.00) 0.4920 to 6.723 0.3702
Upregulated 6 / 17 35.3 1.87
SATB1 nuclear immunoreactivity
Low (IRS≤4) 25 / 61 41.0 (1.00) 0.3831 to 1.390 0.3383
Up (IRS>4) 13 / 41 31.7 0.72
SATB1 cytoplasmic immunoreactivity
Negative (IRS=0) 22 / 71 31.0 (1.00) 0.8869 to 3.549 0.1053
Positive (IRS≥1) 16 / 31 51.6 1.69
Sex
Male 19 / 54 35.2 (1.00) 0.5639 to 2.013 0.8452
Female 19 / 48 39.6 1.07
Age (years)
≤67 11 / 49 22.4 (1.00) 1.481 to 5.310 0.0016*
>67 27 / 53 50.9 2.93
Localization
Cecum, ascending, and transverse colon 11 / 37 29.7 NA NA 0.4005
Descending and sigmoid colon 11 / 26 42.3
Rectum 16 / 39 41.0
Depth of invasion (pT status)
T1+T2 3 / 14 21.4 (1.00) 0.7476 to 4.316 0.1908
T3+T4 35 / 88 39.8 2.15
Lymph nodes (pN status)
N0 13 / 55 23.6 (1.00) 1.501 to 5.482 0.0015*
N1+N2 25 / 47 53.2 2.82
Metastasis (pM status)
M0 25 / 87 28.7 (1.00) 15.37 to 172.5 <0.0001*
M1 13 / 15 86.7 6.44
TNM stage
I–II 9 / 51 17.6 (1.00) 2.104 to 7.611 <0.0001*
III–IV 29 / 51 56.9 4.33
*Significant P values
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comparison to unchanged tissues is a result of mutations and if
there is an association between mutations in SATB1 gene and
impaired SATB1 intracellular targeting.
To assess SATB1 expression in tumor and unchanged
mucosa at the protein level, we used also Western blotting
method. So far, this method has been used by other au-
thors only to study SATB1 expression in cell lines.
SATB1 protein content was the highest in tumor tissues;
however, in contrast to the results of the immunohisto-
chemical analysis, there was no statistically significant
difference in comparison with the unchanged tissues. This
discrepancy could be due to the fact that the results ob-
tained by Western blotting method may be obscured by
the presence of mononuclear cell infiltration in analyzed
tissues.
In the present study, the level of SATB1 expression in CRC
tissues did not correlate with patients’ sex, age, tumor locali-
zation, TNM disease stage, depth of invasion, lymph node
involvement, and the presence of metastases; furthermore, it
had no impact on patients’ overall survival. Previous studies
provided contradictory data about prognostic value of SATB1
expression. Meng et al. [14] revealed a positive correlation of
SATB1 overexpression with the progression of human rectal
cancer. They found that SATB1 expression correlated with
invasive depth and TNM stage at both protein (assessed by
IHC) and mRNA levels. Correlations between mentioned pa-
rameters and SATB1 expression were also reported by Zhang
et al. [16]. In the tissue microarray study, SATB1 overexpres-
sion assessed by IHC alone failed to be a reliable prognostic
marker; however, a strong, significant association was found
between SATB1 expression and female gender, microsatellite
stability, β-catenin overexpression, and SATB2 expression,
but not with any other conventional clinicopathological pa-
rameters [15]. On the contrary, Al-Sohaily et al. [18] observed
that loss of SATB1 expression in the analyzed cohort of 352
CRC patients was an unfavorable prognostic factor. However,
Fig. 5 Analysis of patients’
overall survival. Kaplan-Meier
survival curves of 102 CRC
patients regarding a the
expression levels of SATB1
mRNA and b SATB1 protein, c
nuclear and d cytoplasmic
immunoreactivity of SATB1
protein, e patients’ age, f lymph
node involvement, g the presence
of metastases, and h TNM disease
stage
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ours and the latter study significantly differed in the median
follow-up period which was nearly 36 months in our study
and 66 months in the other one [18].
In summary, SATB1 mRNA and SATB1 protein levels in
tumor tissues differed significantly from those observed in the
normal mucosa; thus, it may be assumed that altered SATB1
expression can precede the CRC-associated lesions. Better
understanding of the mechanisms leading to the alterations
in the control of SATB1 expression in precancerous colorectal
lesions and CRC tissue may provide deeper insight into the
pathogenesis of colorectal cancer.
Acknowledgments This study was supported by statutory grant of the
University of Warmia and Mazury in Olsztyn, Poland, and the National
Science Centre grant N N402 452339. The authors wish to thank Dr.
Aleksandra Piotrowska from the Department of Histology and Embryol-
ogy, Wroclaw Medical University for technical support.
Compliance with ethical standards
Conflicts of interest None
Ethical approval All procedures were performed in accordance with
the ethical standards and were approved by the Bioethics Committee of
the University of Warmia and Mazury in Olsztyn.
Informed consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN
2008. Int J Cancer. 2010;127(12):2893–917.
2. Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, Jayani
RS, et al. Phosphorylation of SATB1, a global gene regulator, acts as
a molecular switch regulating its transcriptional activity in vivo. Mol
Cell. 2006;22(2):231–43.
3. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1
reprogrammes gene expression to promote breast tumour growth
and metastasis. Nature. 2008;452(7184):187–93.
4. Kobierzycki C, Wojnar A, Dziegiel P. Expression of SATB1 protein
in the ductal breast carcinoma tissue microarrays—preliminary study.
Folia Histochem Cytobiol. 2013;51(4):333–8.
5. Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al.
Overexpression of SATB1 in laryngeal squamous cell carcinoma.
ORL J Otorhinolaryngol Relat Spec. 2010;72(1):1–5.
6. Sun F, Lu X, Li H, Peng Z, Wu K, Wang G, et al. Special AT-rich
sequence binding protein 1 regulates the multidrug resistance and
invasion of human gastric cancer cells. Oncol Lett. 2012;4(1):156–
62.
7. TuW, LuoM,Wang Z, YanW, Xia Y, Deng H, et al. Upregulation of
SATB1 promotes tumor growth and metastasis in liver cancer. Liver
Int. 2012;32(7):1064–78.
8. Xiang J, Zhou L, Li S, Xi X, Zhang J, Wang Y, et al. AT-rich se-
quence binding protein 1: contribution to tumor progression and me-
tastasis of human ovarian carcinoma. Oncol Lett. 2012;3(4):865–70.
9. Li QQ, Chen ZQ, Xu JD, Cao XX, Chen Q, Liu XP, et al.
Overexpression and involvement of special AT-rich sequence bind-
ing protein 1 inmultidrug resistance in human breast carcinoma cells.
Cancer Sci. 2010;101(1):80–6.
10. Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ,
Botchkarev VA, Kohwi Y. Genome organizing function of SATB1
in tumor progression. Semin Cancer Biol. 2013;23(2):72–9.
11. Iorns E, HnatyszynHJ, Seo P, Clarke J,Ward T, LippmanM. The role
of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst.
2010;102(16):1284–96.
12. Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L,
Kennedy CW, et al. Loss of special AT-rich binding protein 1 expres-
sion is a marker of poor survival in lung cancer. J Thorac Oncol.
2011;6(7):1179–89.
13. Zhou LY, Liu F, Tong J, Chen QQ, Zhang FW. Expression of special
AT-rich sequence-binding protein mRNA and its clinicopathological
significance in non-small cell lung cancer. Nan Fang Yi Ke Da Xue
Xue Bao. 2009;29(3):534–7.
14. Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al.
Correlation of SATB1 overexpression with the progression of human
rectal cancer. Int J Color Dis. 2012;27(2):143–50.
15. Nodin B, Johannesson H, Wangefjord S, O’Connor DP, Ericson-
Lindquist K, Uhlén M, et al. Molecular correlates and prognostic
significance of SATB1 expression in colorectal cancer. Diagn
Pathol. 2012;7:115.
16. Zhang J, Zhang B, Zhang X, Sun Y, Wei X, McNutt MA, et al.
SATB1 expression is associated with biologic behavior in colorectal
carcinoma in vitro and in vivo. PLoS One. 2013;8(1):e47902.
17. Fang XF, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-
rich sequence-binding protein 1 promotes cell growth and metastasis
in colorectal cancer. World J Gastroenterol. 2013;19(15):2331–9.
18. Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E,
Kohonen-Corish M, et al. Loss of special AT-rich sequence-binding
protein 1 (SATB1) predicts poor survival in patients with colorectal
cancer. Histopathology. 2014;65(2):155–63.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T))
Method. Methods. 2001;25(4):402–8.
20. Bradford MM. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem. 1976;72:248–54.
21. RemmeleW, Stegner HE. Recommendation for uniform definition of
an immunoreactive score (IRS) for immunohistochemical estrogen
receptor detection (ER-ICA) in breast cancer. Pathologe. 1987;8:
138–40.
22. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu
T. The MAR-binding protein SATB1 orchestrates temporal and spa-
tial expression of multiple genes during T-cell development. Genes
Dev. 2000;14(5):521–35.
23. Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, et al.
Involvement of NF-κB/miR-448 regulatory feedback loop in
chemotherapy-induced epithelial-mesenchymal transition of breast
cancer cells. Cell Death Differ. 2011;18(1):16–25.
24. McInnes N, Sadlon TJ, Brown CY, Pederson S, Beyer M, Schultze
JL, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1
in breast cancer cells. Oncogene. 2012;31(8):1045–54.
25. Lakshminarayana Reddy CN, Vyjayanti VN, Notani D, Galande S,
Kotamraju S. Down-regulation of the global regulator SATB1 by
statins in COLO205 colon cancer cells. Mol Med Rep. 2010;3(5):
857–61.
26. Nakayama Y, Mian IS, Kohwi-Shigematsu T, Ogawa T. A nuclear
targeting determinant for SATB1, a genome organizer in the T cell
lineage. Cell Cycle. 2005;4(8):1099–106.
4452 Tumor Biol. (2015) 36:4441–4452
